ABUS - Arbutus Biopharma Corp

ABUS is a company, not a closed-end fund. We still track it - notices about it are below - but most of this site is about funds.

Is anyone targeting this fund?

Yes - 3 large investors hold stakes in this company, and 1 of them is pushing for changes.

What this means for you

Roivant Sciences Ltd. has told the regulator it may push for changes at this company. That usually means asking for a seat on the board, a sale of the company, or a change in how it is run.

Nothing is required of you now.

Large investors can also sell down and walk away. We show every notice they file, the day it is filed.

Email me if this changes

What happened, and when

  1. Oct 27, 2026

    BlackRock now owns 7.2%, as a passive investor.

    Original document →
  2. Oct 7, 2026

    Morgan Stanley now owns 12.2%, as a passive investor.

    Original document →
  3. Oct 5, 2026

    Roivant Sciences Ltd. now owns 19.5%. It has said it may push for changes.

    Original document →
Details: all notices, events and fund facts
Notices from large investors about ABUS
DateInvestorStakeType of notice
Oct 27, 2026 BlackRock 7.2% Updated notice
Oct 7, 2026 Morgan Stanley 12.2% Updated notice
Oct 5, 2026 Roivant Sciences Ltd. 19.5% Updated notice

No announcements from the fund on file. Most funds announce their payout on their own website, not in a filing with the regulator, so a cut or a raise there does not show up here.

Run by
not filed yet
Fund family
not filed yet
Exchange
Nasdaq

See this fund's page at the SEC →

Download this fund's history (CSV)

Follow this fund in a news reader (feed)

Email me when something new is filed for ABUS

Free. One email when a large investor files a notice, or when the fund announces a buy-back, a vote or a closing - usually within a day. No password. Most funds announce payout changes on their own website, where we do not look.